Diagnostic value of HSP90α and Related Markers in Lung Cancer
Abstract Aim: To prove the expression of heat shock protein 90α (HSP90α) in lung cancer and the clinical value of HSP90α and related markers in the diagnosis of lung cancer. Methods: The concentrations of HSP90α and related markers were detected in the blood of 560 lung cancer patients by enzyme-linked immunosorbent assay for analyzing the statistical differences of HSP90α in patients' age, gender, pathological types, tumour staging and metastasis status, as well as the differences and evaluate the value of HSP90α and related markers in lung cancer diagnosis. Results: The results showed no statistical difference in HSP90α among age and gender groups (P>0.05); In the group by lung cancer type, statistical differences were found in the HSP90α level between the small cell lung cancer (SCLC) group and the squamous carcinoma (SLC) group (P<0.05); In the group by staging, the HSP90α level of high staging was significantly higher than that low staging, and the HSP90α level at Ⅰ/Ⅱ/Ⅲ/Ⅳ shows statistical differences among the groups (P<0.05); The test result of HSP90α was higher in the metastatic group than in the non-metastatic group significantly, and the significant difference between the two groups (P<0.05). The r value of the HSP90α and related markers in the diagnosis of lung cancer: NSE>CEA>ProGRP>CF211 (P<0.05). Although HSP90α and related markers didn’t fit the satisfactory conformance, in terms of the positive rate of diagnosis, it were statistically differences in the diagnostic positive rate between HSP90α and each marker (P<0.01). Reducing HSP90α clinical references in lung cancer combined diagnosis can effectively improve the positive rate of the combined diagnosis. Conclusion: HSP90α has significant value on early screening and diagnosis of lung cancer. The combined application of HSP90α and related markers can improve the positive rate of early diagnosis of lung cancer effectively.